OSAM
NAVB

O'Shaughnessy Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-141
Closed – – 2775
2021
Q1 		$0 Hold
141
– – ﹤0.01% 2541
2020
Q4 		$0 Buy
141
+90
+176% +$212 ﹤0.01% 2326
2020
Q3 		$0 Buy
+51
New +$183 ﹤0.01% 2099

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

O'Shaughnessy Asset Management's NAVB Position: Q2 2021 in Review

O'Shaughnessy Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2021, closing a stake of 141 shares.

O'Shaughnessy Asset Management first reported a position in NAVB in Q3 2020 and held it in 3 quarters. The position peaked at $0 in Q1 2021. 31 funds tracked by Wall St. Rank hold NAVB as of Q2 2021.

  • O'Shaughnessy Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 141 Navidea Biopharmaceuticals Inc. shares in Q2 2021.
  • O'Shaughnessy Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2020 and held it in 3 quarters.
  • O'Shaughnessy Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.